Anna Urazov
Hematology-Oncology · Brooklyn, NYNPI 1427580208
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,374 of the $5,308 with a category attached, or 82.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,892, more than ten times the $50 reported in 2022. Among hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $35.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$570
- Merck$568
- Astellas Pharma US Inc$545
- Johnson & Johnson$462
- Seagen Inc.$444
- Exelixis Inc.$385
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,37482%
- Education$93418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 21 | $570 |
| Merck | 11 | $568 |
| Astellas Pharma US Inc | 8 | $545 |
| Johnson & Johnson | 15 | $462 |
| Seagen Inc. | 6 | $444 |
| Exelixis Inc. | 3 | $385 |
| AstraZeneca | 7 | $328 |
| Eisai Inc. | 16 | $297 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $253 |
| Incyte Corporation | 5 | $189 |
| Novartis | 9 | $180 |
| Gilead | 3 | $162 |
| Lilly USA, LLC | 5 | $134 |
| Pfizer | 2 | $115 |
| Agios Pharmaceuticals, Inc. | 3 | $87 |
| Roche Diagnostics Corporation | 1 | $74 |
| Deciphera Pharmaceuticals Inc. | 3 | $68 |
| Taiho Oncology, Inc. | 3 | $67 |
| Accord Healthcare, Inc. | 2 | $59 |
| Boehringer Ingelheim | 2 | $40 |
| Sanofi | 1 | $35 |
| Bayer | 2 | $34 |
| Genmab U.S., Inc. | 1 | $30 |
| Bristol Myers Squibb | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| GSK | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Syndax Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,308 in reported general payments places this provider in the 95th percentile of 38 hematology-oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 15 | $3,246 |
| Anastrozole | 106 | $1,586 |
| Letrozole | 30 | $595 |
| Tamoxifen Citrate | 18 | $271 |
| Alendronate Sodium | 12 | $63 |
| Ondansetron OdtOndansetron | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Brooklyn
- Neha MaithelBrooklyn$1K
- Rami DayaBrooklyn$767
- Tsering Lama TamangBrooklyn$692
- Taral ShahBrooklyn$384
- Angelica SinghBrooklyn$56
- Amy SharmaBronx$11K
- Sherry HsuNew York$4K
- Xuan GeBronx$4K
- Ioannis MantzarisBronx$3K
- Nirmala ShevdeNew Hyde Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.